GlassScriptPhysician profile
Andrea S Ching
NPI 1669495214
$31,407.50
in general payments reported to CMS, 2019-2025
20 companies · $558 in 2025
The $558 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $41.42 · 2021: $332 · 2022: $225 · 2023: $277 · 2024: $251 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $29,416.60 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $438.31 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $354.93 | 2021-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Sight Sciences, INC. | $314.15 | 2021-2024 | Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $168.99 | 2019-2023 | Tecnis Iol |
| Abbvie INC. | $161.05 | 2022-2025 | Durysta |
| Kala Pharmaceuticals, INC. | $68.70 | 2021-2022 | |
| Beaver-Visitec International, INC. | $68.47 | 2019 | |
| Oyster Point Pharma, INC. | $62.82 | 2024-2025 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $61.58 | 2022 | |
| Allergan, INC. | $53.41 | 2019-2021 | |
| Amgen INC. | $45.54 | 2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $39.36 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $37.38 | 2019-2021 | |
| New World Medical,INC. | $26.19 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $22.66 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.09 | 2020 | |
| Glaxosmithkline, LLC. | $17.51 | 2019 | |
| Bausch & Lomb Americas INC. | $15.65 | 2025 | Envista Envy Iol, Envista Aspire Toric Iol |
| Aerie Pharmaceuticals, INC. | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Ching listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.